A randomized, double-blind, parallel-group, multicentre, phase III study to assess the effect of esomeprazole 20 and 40 mg od versus placebo on the occurrence of peptic ulcers during 26 weeks in subjects on continuous low dose acetylsalicylic acid (ASA).

Trial Profile

A randomized, double-blind, parallel-group, multicentre, phase III study to assess the effect of esomeprazole 20 and 40 mg od versus placebo on the occurrence of peptic ulcers during 26 weeks in subjects on continuous low dose acetylsalicylic acid (ASA).

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Feb 2017

At a glance

  • Drugs Esomeprazole (Primary)
  • Indications NSAID-induced ulcer
  • Focus Registrational; Therapeutic Use
  • Acronyms OBERON
  • Sponsors AstraZeneca
  • Most Recent Events

    • 17 Mar 2011 Results published in the Heart.
    • 25 Nov 2009 Results presented at GASTRO 2009.
    • 30 May 2009 Results have been presented at DDW 2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top